{
  "title": "Coronaviruses",
  "story": [
    {
      "type": "markdown",
      "id": "bdc02a26a3a6cd01",
      "text": "https://www.ncbi.nlm.nih.gov/books/NBK349040/box/box_6-1/?report=objectonly\n"
    },
    {
      "type": "markdown",
      "id": "49cd14239884eea0",
      "text": "Coronaviruses were first identified in the 1960s\n"
    },
    {
      "type": "markdown",
      "id": "aab62dd7cc8f3422",
      "text": "Named for the crown-like spike proteins (S proteins) on the surface, which are the target of current vaccination efforts\n"
    },
    {
      "type": "markdown",
      "id": "c853fbcb73db271e",
      "text": "Found in many animals, including bats\n"
    },
    {
      "type": "markdown",
      "id": "922ecf20da89f282",
      "text": "Six human coronaviruses have been identified: four cause mild, seasonal disease (“common cold”), two cause severe disease (severe acute respiratory syndrome, or SARS, and Middle East respiratory syndrome, or MERS)\n\n"
    },
    {
      "type": "markdown",
      "id": "a74ac99002f8e0ec",
      "text": "# SARS Epidemic (2002-2003)\n8,098 probable cases and 774 deaths (10 percent fatality rate)\n"
    },
    {
      "type": "markdown",
      "id": "e2a786b3cee00dde",
      "text": "Estimated economic losses of more than $30 billion\nAssociation of cases with “superspreading events” (e.g., from one hotel guest to many others and their contacts)\n"
    },
    {
      "type": "markdown",
      "id": "ceb3db65a25be979",
      "text": "Experts concerned that transmissibility increased over the course of the epidemic, associated with changes to the S protein\n"
    },
    {
      "type": "markdown",
      "id": "1eb617f3481a4da6",
      "text": "Control strategies: surveillance to identify cases, isolation of ill persons, quarantine of exposed persons, good infection control to prevent onward transmission\n\n"
    },
    {
      "type": "markdown",
      "id": "c988662f1c75a73a",
      "text": "# MERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\n"
    },
    {
      "type": "markdown",
      "id": "359515c65e243304",
      "text": "Demographics: 66 percent male, median age 50, most with underlying health conditions\n"
    },
    {
      "type": "markdown",
      "id": "0f988642a5a87f37",
      "text": "Transmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\n"
    },
    {
      "type": "markdown",
      "id": "dae9b5bcd9f7f86d",
      "text": "No established treatment or vaccines (investigational products in development)\n"
    },
    {
      "type": "markdown",
      "id": "01ccb580f0efa8fa",
      "text": "Epidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\n"
    },
    {
      "type": "markdown",
      "id": "a89d43d5b1014d5b",
      "text": "SOURCE: Swerdlow presentation, March 27, 2015.\nFrom: [https://www.ncbi.nlm.nih.gov/books/NBK349040/ 6, Developing MCMs for Coronaviruses]\n\n"
    },
    {
      "type": "markdown",
      "id": "f3abb71190bae670",
      "text": "Cover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
    }
  ],
  "journal": [
    {
      "type": "create",
      "item": {
        "title": "Coronaviruses",
        "story": []
      },
      "date": 1626503124595
    },
    {
      "item": {
        "type": "factory",
        "id": "bdc02a26a3a6cd01"
      },
      "id": "bdc02a26a3a6cd01",
      "type": "add",
      "date": 1626503135343
    },
    {
      "type": "edit",
      "id": "bdc02a26a3a6cd01",
      "item": {
        "type": "markdown",
        "id": "bdc02a26a3a6cd01",
        "text": "https://www.ncbi.nlm.nih.gov/books/NBK349040/box/box_6-1/?report=objectonly\n"
      },
      "date": 1626503140480
    },
    {
      "item": {
        "type": "factory",
        "id": "49cd14239884eea0"
      },
      "id": "49cd14239884eea0",
      "type": "add",
      "after": "bdc02a26a3a6cd01",
      "date": 1626503151216
    },
    {
      "type": "edit",
      "id": "49cd14239884eea0",
      "item": {
        "type": "markdown",
        "id": "49cd14239884eea0",
        "text": "BOX 6-1Coronaviruses\nFirst identified in the 1960s\nNamed for the crown-like spike proteins (S proteins) on the surface, which are the target of current vaccination efforts\nFound in many animals, including bats\nSix human coronaviruses have been identified: four cause mild, seasonal disease (“common cold”), two cause severe disease (severe acute respiratory syndrome, or SARS, and Middle East respiratory syndrome, or MERS)\nSARS Epidemic (2002-2003)\n8,098 probable cases and 774 deaths (10 percent fatality rate)\nEstimated economic losses of more than $30 billion\nAssociation of cases with “superspreading events” (e.g., from one hotel guest to many others and their contacts)\nExperts concerned that transmissibility increased over the course of the epidemic, associated with changes to the S protein\nControl strategies: surveillance to identify cases, isolation of ill persons, quarantine of exposed persons, good infection control to prevent onward transmission\nMERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\nDemographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\nSOURCE: Swerdlow presentation, March 27, 2015.\n\nFrom: 6, Developing MCMs for Coronaviruses\n\nCover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
      },
      "date": 1626503154647
    },
    {
      "type": "edit",
      "id": "49cd14239884eea0",
      "item": {
        "type": "markdown",
        "id": "49cd14239884eea0",
        "text": "Coronaviruses were first identified in the 1960s\n"
      },
      "date": 1626503174896
    },
    {
      "type": "add",
      "id": "aab62dd7cc8f3422",
      "item": {
        "type": "markdown",
        "id": "aab62dd7cc8f3422",
        "text": "Named for the crown-like spike proteins (S proteins) on the surface, which are the target of current vaccination efforts\nFound in many animals, including bats\nSix human coronaviruses have been identified: four cause mild, seasonal disease (“common cold”), two cause severe disease (severe acute respiratory syndrome, or SARS, and Middle East respiratory syndrome, or MERS)\nSARS Epidemic (2002-2003)\n8,098 probable cases and 774 deaths (10 percent fatality rate)\nEstimated economic losses of more than $30 billion\nAssociation of cases with “superspreading events” (e.g., from one hotel guest to many others and their contacts)\nExperts concerned that transmissibility increased over the course of the epidemic, associated with changes to the S protein\nControl strategies: surveillance to identify cases, isolation of ill persons, quarantine of exposed persons, good infection control to prevent onward transmission\nMERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\nDemographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\nSOURCE: Swerdlow presentation, March 27, 2015.\n\nFrom: 6, Developing MCMs for Coronaviruses\n\nCover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
      },
      "after": "49cd14239884eea0",
      "date": 1626503178969
    },
    {
      "type": "edit",
      "id": "aab62dd7cc8f3422",
      "item": {
        "type": "markdown",
        "id": "aab62dd7cc8f3422",
        "text": "Named for the crown-like spike proteins (S proteins) on the surface, which are the target of current vaccination efforts\n"
      },
      "date": 1626503195763
    },
    {
      "type": "add",
      "id": "c853fbcb73db271e",
      "item": {
        "type": "markdown",
        "id": "c853fbcb73db271e",
        "text": "Found in many animals, including bats\nSix human coronaviruses have been identified: four cause mild, seasonal disease (“common cold”), two cause severe disease (severe acute respiratory syndrome, or SARS, and Middle East respiratory syndrome, or MERS)\n\n"
      },
      "after": "aab62dd7cc8f3422",
      "date": 1626503199423
    },
    {
      "type": "add",
      "id": "a74ac99002f8e0ec",
      "item": {
        "type": "markdown",
        "id": "a74ac99002f8e0ec",
        "text": "SARS Epidemic (2002-2003)\n8,098 probable cases and 774 deaths (10 percent fatality rate)\nEstimated economic losses of more than $30 billion\nAssociation of cases with “superspreading events” (e.g., from one hotel guest to many others and their contacts)\nExperts concerned that transmissibility increased over the course of the epidemic, associated with changes to the S protein\nControl strategies: surveillance to identify cases, isolation of ill persons, quarantine of exposed persons, good infection control to prevent onward transmission\nMERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\nDemographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\nSOURCE: Swerdlow presentation, March 27, 2015.\n\nFrom: 6, Developing MCMs for Coronaviruses\n\nCover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
      },
      "after": "c853fbcb73db271e",
      "date": 1626503205015
    },
    {
      "type": "edit",
      "id": "c853fbcb73db271e",
      "item": {
        "type": "markdown",
        "id": "c853fbcb73db271e",
        "text": "Found in many animals, including bats\n"
      },
      "date": 1626503206798
    },
    {
      "type": "add",
      "id": "922ecf20da89f282",
      "item": {
        "type": "markdown",
        "id": "922ecf20da89f282",
        "text": "Six human coronaviruses have been identified: four cause mild, seasonal disease (“common cold”), two cause severe disease (severe acute respiratory syndrome, or SARS, and Middle East respiratory syndrome, or MERS)\n\n"
      },
      "after": "c853fbcb73db271e",
      "date": 1626503208303
    },
    {
      "type": "edit",
      "id": "a74ac99002f8e0ec",
      "item": {
        "type": "markdown",
        "id": "a74ac99002f8e0ec",
        "text": "# SARS Epidemic (2002-2003)\n8,098 probable cases and 774 deaths (10 percent fatality rate)\nEstimated economic losses of more than $30 billion\nAssociation of cases with “superspreading events” (e.g., from one hotel guest to many others and their contacts)\nExperts concerned that transmissibility increased over the course of the epidemic, associated with changes to the S protein\nControl strategies: surveillance to identify cases, isolation of ill persons, quarantine of exposed persons, good infection control to prevent onward transmission\nMERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\nDemographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\nSOURCE: Swerdlow presentation, March 27, 2015.\n\nFrom: 6, Developing MCMs for Coronaviruses\n\nCover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
      },
      "date": 1626503241721
    },
    {
      "type": "edit",
      "id": "a74ac99002f8e0ec",
      "item": {
        "type": "markdown",
        "id": "a74ac99002f8e0ec",
        "text": "# SARS Epidemic (2002-2003)\n8,098 probable cases and 774 deaths (10 percent fatality rate)\nEstimated economic losses of more than $30 billion\nAssociation of cases with “superspreading events” (e.g., from one hotel guest to many others and their contacts)\nExperts concerned that transmissibility increased over the course of the epidemic, associated with changes to the S protein\nControl strategies: surveillance to identify cases, isolation of ill persons, quarantine of exposed persons, good infection control to prevent onward transmission\n\n"
      },
      "date": 1626503253848
    },
    {
      "type": "add",
      "id": "c988662f1c75a73a",
      "item": {
        "type": "markdown",
        "id": "c988662f1c75a73a",
        "text": "# MERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\nDemographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\nSOURCE: Swerdlow presentation, March 27, 2015.\n\nFrom: 6, Developing MCMs for Coronaviruses\n\nCover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
      },
      "after": "a74ac99002f8e0ec",
      "date": 1626503260395
    },
    {
      "type": "edit",
      "id": "c988662f1c75a73a",
      "item": {
        "type": "markdown",
        "id": "c988662f1c75a73a",
        "text": "# MERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\nDemographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\nSOURCE: Swerdlow presentation, March 27, 2015.\nFrom: [https://www.ncbi.nlm.nih.gov/books/NBK349040/ 6, Developing MCMs for Coronaviruses]\n\n\nCover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
      },
      "date": 1626503319299
    },
    {
      "type": "edit",
      "id": "c988662f1c75a73a",
      "item": {
        "type": "markdown",
        "id": "c988662f1c75a73a",
        "text": "# MERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\nDemographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\n"
      },
      "date": 1626503333265
    },
    {
      "type": "add",
      "id": "a89d43d5b1014d5b",
      "item": {
        "type": "markdown",
        "id": "a89d43d5b1014d5b",
        "text": "SOURCE: Swerdlow presentation, March 27, 2015.\nFrom: [https://www.ncbi.nlm.nih.gov/books/NBK349040/ 6, Developing MCMs for Coronaviruses]\n\n"
      },
      "after": "c988662f1c75a73a",
      "date": 1626503337953
    },
    {
      "type": "add",
      "id": "f3abb71190bae670",
      "item": {
        "type": "markdown",
        "id": "f3abb71190bae670",
        "text": "Cover of Rapid Medical Countermeasure Response to Infectious Diseases\nRapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.\nForum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine.\nWashington (DC): National Academies Press (US); 2016 Feb 12.\nCopyright 2016 by the National Academy of Sciences. All rights reserved.\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health."
      },
      "after": "a89d43d5b1014d5b",
      "date": 1626503459514
    },
    {
      "type": "edit",
      "id": "a74ac99002f8e0ec",
      "item": {
        "type": "markdown",
        "id": "a74ac99002f8e0ec",
        "text": "# SARS Epidemic (2002-2003)\n8,098 probable cases and 774 deaths (10 percent fatality rate)\n"
      },
      "date": 1626503467160
    },
    {
      "type": "add",
      "id": "e2a786b3cee00dde",
      "item": {
        "type": "markdown",
        "id": "e2a786b3cee00dde",
        "text": "Estimated economic losses of more than $30 billion\nAssociation of cases with “superspreading events” (e.g., from one hotel guest to many others and their contacts)\n"
      },
      "after": "a74ac99002f8e0ec",
      "date": 1626503471939
    },
    {
      "type": "add",
      "id": "ceb3db65a25be979",
      "item": {
        "type": "markdown",
        "id": "ceb3db65a25be979",
        "text": "Experts concerned that transmissibility increased over the course of the epidemic, associated with changes to the S protein\n"
      },
      "after": "e2a786b3cee00dde",
      "date": 1626503474371
    },
    {
      "type": "add",
      "id": "1eb617f3481a4da6",
      "item": {
        "type": "markdown",
        "id": "1eb617f3481a4da6",
        "text": "Control strategies: surveillance to identify cases, isolation of ill persons, quarantine of exposed persons, good infection control to prevent onward transmission\n\n"
      },
      "after": "ceb3db65a25be979",
      "date": 1626503476651
    },
    {
      "type": "edit",
      "id": "c988662f1c75a73a",
      "item": {
        "type": "markdown",
        "id": "c988662f1c75a73a",
        "text": "# MERS Outbreak (2012-present)\n1,075 total cases confirmed by World Health Organization, 404 deaths (38 percent fatality rate)\nMost cases in Saudi Arabia (951 cases, 372 deaths), cases exported to 19 countries\n221 cases since August 2014, primarily Middle East, with some recent cases in Europe, Asia\nTwo U.S. cases (Florida, Indiana) were health care workers who worked in Saudi Arabia and traveled home; no secondary cases among contacts\n"
      },
      "date": 1626504267409
    },
    {
      "type": "add",
      "id": "359515c65e243304",
      "item": {
        "type": "markdown",
        "id": "359515c65e243304",
        "text": "Demographics: 66 percent male, median age 50, most with underlying health conditions\nTransmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\n"
      },
      "after": "c988662f1c75a73a",
      "date": 1626504268742
    },
    {
      "type": "edit",
      "id": "359515c65e243304",
      "item": {
        "type": "markdown",
        "id": "359515c65e243304",
        "text": "Demographics: 66 percent male, median age 50, most with underlying health conditions\n"
      },
      "date": 1626504273332
    },
    {
      "type": "add",
      "id": "0f988642a5a87f37",
      "item": {
        "type": "markdown",
        "id": "0f988642a5a87f37",
        "text": "Transmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\nNo established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\n"
      },
      "after": "359515c65e243304",
      "date": 1626504273868
    },
    {
      "type": "edit",
      "id": "0f988642a5a87f37",
      "item": {
        "type": "markdown",
        "id": "0f988642a5a87f37",
        "text": "Transmission likely respiratory: human to human (not sustained), health care associated outbreaks, animal sources (bats, camels)\n"
      },
      "date": 1626504282241
    },
    {
      "type": "add",
      "id": "dae9b5bcd9f7f86d",
      "item": {
        "type": "markdown",
        "id": "dae9b5bcd9f7f86d",
        "text": "No established treatment or vaccines (investigational products in development)\nEpidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\n"
      },
      "after": "0f988642a5a87f37",
      "date": 1626504289284
    },
    {
      "type": "edit",
      "id": "dae9b5bcd9f7f86d",
      "item": {
        "type": "markdown",
        "id": "dae9b5bcd9f7f86d",
        "text": "No established treatment or vaccines (investigational products in development)\n"
      },
      "date": 1626504315496
    },
    {
      "type": "add",
      "id": "01ccb580f0efa8fa",
      "item": {
        "type": "markdown",
        "id": "01ccb580f0efa8fa",
        "text": "Epidemiological and laboratory activities in the United States included developing and broadly disseminating case definitions, infection control guidance, travelers health recommendations, epidemiology toolkits, serology, and polymerase chain reaction diagnostics.\n"
      },
      "after": "dae9b5bcd9f7f86d",
      "date": 1626504318870
    }
  ]
}